Abstract

If we will provide a better understadning of underlying mechanisms of myelomagenesis, then we will be able to reach are goals to (1) define high-risk precursor disease patinets, and to (2) delay and prevent development of multiple myeloma. For example, in 2010, we have developed the first treatment study for smoldering myeloma in the world, using a novel treatment approach;we are planning on using a new modality (a monoclonal antibody which targets natural killer cells, which in turn will cause anti-myeloma effect). If we will be able to reach our goals that will have a major impact on the clinical management and outcome of multiple myeloma in the future.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011352-01
Application #
8157787
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2010
Total Cost
$551,509
Indirect Cost

  Institution

Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Liden, Y; Olofsson, N; Landgren, O et al. (2012) Pain and anxiety during bone marrow aspiration/biopsy: Comparison of ratings among patients versus health-care professionals. Eur J Oncol Nurs 16:323-9
Kwok, Mary; Korde, Neha; Landgren, Ola (2012) Bortezomib to treat the TEMPI syndrome. N Engl J Med 366:1843-5
Engels, E A; Preiksaitis, J; Zingone, A et al. (2012) Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. Am J Transplant 12:1268-74
Shebl, Fatma M; Yu, Kai; Landgren, Ola et al. (2012) Increased levels of circulating cytokines with HIV-related immunosuppression. AIDS Res Hum Retroviruses 28:809-15
Ludwig, Heinz; Durie, Brian G M; McCarthy, Philip et al. (2012) IMWG consensus on maintenance therapy in multiple myeloma. Blood 119:3003-15
Kumar, S K; Lee, J H; Lahuerta, J J et al. (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26:149-57
Kristinsson, Sigurdur Yngvi; Landgren, Ola (2012) Thromboprophylaxis in multiple myeloma: is the evidence there? Expert Rev Anticancer Ther 12:291-4
Thomas, Anish; Mailankody, Sham; Korde, Neha et al. (2012) Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 119:2731-7
Tembhare, Prashant; Yuan, Constance; Korde, Neha et al. (2012) Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression. Leuk Lymphoma 53:721-4
Landgren, O; Ma, W; Kyle, R A et al. (2012) Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 26:844-5

Showing the most recent 10 out of 36 publications